Disease block
E70-E90 – Stoffwechselstörungen
- Chapter IV: Endokrine, Ernährungs- und Stoffwechselkrankheiten
105Decisions
131Patient groups
Added benefit by patient group
- Major7
- Considerable9
- Minor5
- Non-quantifiable38
- Not proven71
- Lesser benefit1
Diseases in this disease block
- E70 Störungen des Stoffwechsels aromatischer Aminosäuren 2 decisions
- E72 Sonstige Störungen des Aminosäurestoffwechsels 4 decisions
- E74 Sonstige Störungen des Kohlenhydratstoffwechsels 2 decisions
- E75 Störungen des Sphingolipidstoffwechsels und sonstige Störungen der Lipidspeicherung 7 decisions
- E76 Störungen des Glykosaminoglykan-Stoffwechsels 2 decisions
- E77 Störungen des Glykoproteinstoffwechsels 1 decision
- E78 Störungen des Lipoproteinstoffwechsels und sonstige Lipidämien 15 decisions
- E80 Störungen des Porphyrin- und Bilirubinstoffwechsels 2 decisions
- E83 Störungen des Mineralstoffwechsels 5 decisions
- E84 Zystische Fibrose 48 decisions
- E85 Amyloidose 12 decisions
- E87 Sonstige Störungen des Wasser- und Elektrolythaushaltes sowie des Säure-Basen-Gleichgewichts 3 decisions
- E88 Sonstige Stoffwechselstörungen 1 decision
- E89 Endokrine und Stoffwechselstörungen nach medizinischen Maßnahmen, anderenorts nicht klassifiziert 1 decision
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-05-21TryngolzaOlezarsenMinor
- 2026-05-07AttrogyDiflunisalNot proven
- 2026-01-22AmvuttraVutrisiranNot proven
- 2026-01-22SephienceSepiapterinNon-quantifiable
- 2025-10-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2025-10-16KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor: 1 of 3 patient groupsConsiderable: 1 of 3 patient groupsNon-quantifiable: 1 of 3 patient groups
- 2025-10-16WainzuaEplontersenNot proven
- 2025-09-18BeyonttraAcoramidisNot proven
- 2025-09-04NulibryFosdenopterinNon-quantifiable
- 2025-08-21DarzalexDaratumumabConsiderable
- 2025-06-18CerdelgaEliglustatNon-quantifiable
- 2024-08-01VeltassaPatiromerNot proven
- 2024-07-04EvkeezaEvinacumabNot proven
- 2024-07-04EvkeezaEvinacumabNot proven
- 2024-07-04LoargysPegzilarginaseNon-quantifiable
- 2024-06-20YorvipathPalopegteriparatidNot proven
- 2024-06-06PraluentAlirocumabNot proven: 2 of 2 patient groups
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2024-05-16OnpattroPatisiranLesser benefit
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2024-03-21ElfabrioPegunigalsidase alfaNot proven
- 2024-02-15GalafoldMigalastatNot proven
- 2024-02-01PombilitiCipaglucosidase alfaMinor
- 2024-01-18OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2023-04-06AmvuttraVutrisiranMinor
- 2023-02-16CrysvitaBurosumabNot proven
- 2022-12-15BrineuraCerliponase alfaMajor
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNon-quantifiable
- 2022-08-04KalydecoIvacaftorConsiderable
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorConsiderable
- 2022-07-21CrysvitaBurosumabNot proven
- 2022-07-21CrysvitaBurosumabNon-quantifiable
- 2022-06-16RepathaEvolocumabNot proven: 4 of 4 patient groups
- 2022-05-05VazkepaIcosapent-EthylNot proven
- 2022-03-18OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2022-01-20DarzalexDaratumumabNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-04LibmeldyAtidarsagen autotemcelMajor: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2021-09-16LokelmaNatrium-ZirconiumcyclosilicatNot proven
- 2021-07-15LeqvioInclisiranNot proven: 2 of 2 patient groups
- 2021-07-01ScenesseAfamelanotidNon-quantifiable
- 2021-07-01OxlumoLumasiranNon-quantifiable
- 2021-06-03VelphoroSucroferric OxyhydroxideNot proven
- 2021-06-03KanumaSebelipase alfaNon-quantifiable: 2 of 2 patient groups
- 2021-05-20KalydecoIvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNon-quantifiable
- 2021-05-20VyndaqelTafamidisConsiderable
- 2021-05-20VyndaqelTafamidisNot proven
- 2021-05-20SymkeviTezacaftor/IvacaftorNot proven
- 2021-05-20SymkeviTezacaftor/IvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNon-quantifiable
- 2021-04-15NustendiBempedoinsäure/EzetimibNot proven: 2 of 2 patient groups
- 2021-04-15NilemdoBempedoinsäureNot proven: 2 of 2 patient groups
- 2021-02-18KalydecoIvacaftorMajor
- 2021-02-18KalydecoIvacaftorMajor
- 2021-02-18KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor
- 2021-02-18KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor
- 2020-12-17KalydecoIvacaftorNon-quantifiable: 2 of 2 patient groups
- 2020-12-17SymkeviTezacaftor/IvacaftorNot proven
- 2020-12-17SymkeviTezacaftor/IvacaftorNot proven
- 2020-10-15Givlaari GivosiranConsiderable
- 2020-06-04KalydecoIvacaftorNon-quantifiable
- 2020-04-02StrensiqAsfotase alfaNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2020-02-20KalydecoIvacaftorMinor
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorNot proven
- 2020-02-20KalydecoIvacaftorNot proven
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20WaylivraVolanesorsenNon-quantifiable
- 2020-02-20KalydecoIvacaftorConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2019-12-19PalynziqPegvaliaseNon-quantifiable
- 2019-07-04RavictiGlycerolphenylbutyratNon-quantifiable
- 2019-05-02PraluentAlirocumabNot proven: 4 of 4 patient groups
- 2019-03-22MepseviiVestronidase alfaNon-quantifiable
- 2019-03-22OnpattroPatisiranConsiderable
- 2019-03-22MyaleptaMetreleptinNon-quantifiable: 2 of 2 patient groups
- 2019-03-22TegsediInotersenNon-quantifiable
- 2018-12-20LamzedeVelmanase alfaNon-quantifiable
- 2018-09-20VeltassaPatiromerNot proven
- 2018-09-06RepathaEvolocumabNot proven: 3 of 3 patient groups
- 2018-08-16RavictiGlycerolphenylbutyratNon-quantifiable
- 2018-08-02OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2018-03-16VimizimElosulfase alfaMinor
- 2016-06-02OrkambiLumacaftor/IvacaftorConsiderable
- 2016-05-04PraluentAlirocumabNot proven
- 2016-03-09RepathaEvolocumabNot proven: 4 of 4 patient groups
- 2015-11-27LojuxtaLomitapidNot proven: 3 of 3 patient groups
- 2015-10-01CerdelgaEliglustatNon-quantifiable
Data status: 2026-10-29